PRKN and Parkinson disease: Of the 123 patients with Parkinson disease–associated genetic mutations, 115 (93.5%; 46 LRRK2, 33 GBA, 18 homozygous PRKN, and 18 heterozygous PRKN) were included in the meta-analysis for motor end points, and 8 single cases (6.5%) underwent intraindividual patient analyses (Tables 1 and 3).